Robin Doroff
Overview
Explore the profile of Robin Doroff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weycker D, Doroff R, Hanau A, Bowers C, Belani R, Chandler D, et al.
BMC Cancer
. 2019 Aug;
19(1):792.
PMID: 31399079
Background: Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy. Clinical practice guidelines recommend routine prophylactic coverage with granulocyte colony-stimulating factor (G-CSF)-such as pegfilgrastim-for most patients receiving chemotherapy with...
2.
Weycker D, Bensink M, Lonshteyn A, Doroff R, Chandler D
Curr Med Res Opin
. 2018 Dec;
35(6):1073-1080.
PMID: 30550346
Background: Guidelines recommend primary prophylactic use of colony-stimulating factor (PP-CSF) when risk of febrile neutropenia (FN) - based on chemotherapy and patient risk factors - is high. Whether and how...
3.
Vincent J, Nielsen N, Shapiro N, Gerbasi M, Grossman A, Doroff R, et al.
Ann Intensive Care
. 2018 Nov;
8(1):107.
PMID: 30411243
Background: Maintenance of mean arterial pressure (MAP) at levels sufficient to avoid tissue hypoperfusion is a key tenet in the management of distributive shock. We hypothesized that patients with distributive...
4.
Pelton S, Bornheimer R, Doroff R, Shea K, Sato R, Weycker D
Clin Infect Dis
. 2018 Sep;
68(11):1831-1838.
PMID: 30239637
Background: Following introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in the United States, epidemiology of pneumococcal disease shifted such that disease incidence in the elderly exceeded that in children. We...
5.
Weycker D, Bensink M, Lonshteyn A, Doroff R, Chandler D
Curr Med Res Opin
. 2017 Sep;
33(12):2107-2113.
PMID: 28958157
Objective: Pegfilgrastim prophylaxis (PP) is recommended 1-3 days following administration of chemotherapy during the cycle. Some patients, however, receive PP before or after the recommended timing. While evidence suggests that...
6.
Weycker D, Bensink M, Wu H, Doroff R, Chandler D
Curr Med Res Opin
. 2017 Sep;
33(12):2115-2120.
PMID: 28958156
Objective: Evidence suggests that not all cancer chemotherapy patients who receive first-cycle pegfilgrastim prophylaxis (PP) continue to receive it in later cycles, and that these patients may be subsequently at...